Orchestra BioMed Holdings, Inc. (OBIO)
NASDAQ: OBIO · Real-Time Price · USD
4.400
-0.280 (-5.98%)
At close: Dec 5, 2025, 4:00 PM EST
4.470
+0.070 (1.59%)
After-hours: Dec 5, 2025, 4:47 PM EST
Orchestra BioMed Holdings Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Orchestra BioMed Holdings stock have an average target of 13.67, with a low estimate of 10 and a high estimate of 20. The average target predicts an increase of 210.68% from the current stock price of 4.40.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Orchestra BioMed Holdings stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Maintains $20 | Strong Buy | Maintains | $20 | +354.55% | Nov 13, 2025 |
| Barclays | Barclays | Buy Maintains $12 → $11 | Buy | Maintains | $12 → $11 | +150.00% | Nov 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $12 → $10 | Strong Buy | Maintains | $12 → $10 | +127.27% | Sep 4, 2025 |
| BTIG | BTIG | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Aug 20, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $20 | Strong Buy | Maintains | $20 | +354.55% | Aug 13, 2025 |
Financial Forecast
Revenue This Year
3.60M
from 2.64M
Increased by 36.43%
Revenue Next Year
3.69M
from 3.60M
Increased by 2.56%
EPS This Year
-1.79
from -1.66
EPS Next Year
-1.60
from -1.79
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 4.2M | 4.8M | ||||
| Avg | 3.6M | 3.7M | ||||
| Low | 3.1M | 2.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 59.2% | 34.2% | ||||
| Avg | 36.4% | 2.6% | ||||
| Low | 18.9% | -26.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.82 | -1.52 | ||||
| Avg | -1.79 | -1.60 | ||||
| Low | -1.74 | -1.61 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.